February 21, 2019 10:13 AM EST
Pharma

Dear Bernie: Cat­a­lyst CEO McE­nany de­fends his $375,000 price tag on an old drug once of­fered for free

John Carroll

Editor & Founder

Now that Cat­a­lyst has tak­en cen­ter stage as this quar­ter’s most fre­quent­ly pil­lo­ried price gouger, the com­pa­ny $CPRX is try­ing to take a stand in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times